Canada markets open in 7 hours 1 minute

Crescita Therapeutics Inc. (CTX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.4000+0.0100 (+2.56%)
At close: 03:59PM EDT
Full screen
Previous Close0.3900
Open0.4000
Bid0.3800 x 0
Ask0.4000 x 0
Day's Range0.4000 - 0.4200
52 Week Range0.3600 - 0.7300
Volume5,090
Avg. Volume20,088
Market Cap7.817M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Crescita Reports Q4 and Fiscal 2023 Results

    LAVAL, Quebec, March 13, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 ("Q4-2023" and "F2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted, and in accordance with International Financial Reporting Standards ("IFRS") as issued by

  • Business Wire

    Crescita Reports Third Quarter 2023 Results

    LAVAL, Québec, November 08, 2023--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2023 ("Q3-2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted.

  • Business Wire

    Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

    LAVAL, Quebec, August 29, 2023--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company") announced today that the Toronto Stock Exchange (the "TSX") has approved the Company’s proposed normal course issuer bid ("NCIB") to purchase up to a maximum of 1,821,616 common shares ("Common Shares") for cancellation, representing approximately 10% of its public float as of August 18, 2023, as appropriate opportunities arise from time to time. As of August 27, 2023, the Company